nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Weight decreased—Sorafenib—thyroid cancer	0.00529	0.00529	CcSEcCtD
Milnacipran—Convulsion—Vandetanib—thyroid cancer	0.00523	0.00523	CcSEcCtD
Milnacipran—Hypertension—Vandetanib—thyroid cancer	0.00521	0.00521	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00517	0.00517	CcSEcCtD
Milnacipran—Chest pain—Vandetanib—thyroid cancer	0.00514	0.00514	CcSEcCtD
Milnacipran—Anxiety—Vandetanib—thyroid cancer	0.00512	0.00512	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0051	0.0051	CcSEcCtD
Milnacipran—Dry mouth—Vandetanib—thyroid cancer	0.00503	0.00503	CcSEcCtD
Milnacipran—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00493	0.00493	CcSEcCtD
Milnacipran—Infection—Vandetanib—thyroid cancer	0.00489	0.00489	CcSEcCtD
Milnacipran—Nervous system disorder—Vandetanib—thyroid cancer	0.00483	0.00483	CcSEcCtD
Milnacipran—Thrombocytopenia—Vandetanib—thyroid cancer	0.00482	0.00482	CcSEcCtD
Milnacipran—Skin disorder—Vandetanib—thyroid cancer	0.00478	0.00478	CcSEcCtD
Milnacipran—Urinary tract disorder—Sorafenib—thyroid cancer	0.00462	0.00462	CcSEcCtD
Milnacipran—Connective tissue disorder—Sorafenib—thyroid cancer	0.0046	0.0046	CcSEcCtD
Milnacipran—Urethral disorder—Sorafenib—thyroid cancer	0.00458	0.00458	CcSEcCtD
Milnacipran—Insomnia—Vandetanib—thyroid cancer	0.00446	0.00446	CcSEcCtD
Milnacipran—Paraesthesia—Vandetanib—thyroid cancer	0.00442	0.00442	CcSEcCtD
Milnacipran—Erythema multiforme—Sorafenib—thyroid cancer	0.00442	0.00442	CcSEcCtD
Milnacipran—Dyspnoea—Vandetanib—thyroid cancer	0.00439	0.00439	CcSEcCtD
Milnacipran—Flushing—Sorafenib—thyroid cancer	0.00434	0.00434	CcSEcCtD
Milnacipran—Cardiac disorder—Sorafenib—thyroid cancer	0.00434	0.00434	CcSEcCtD
Milnacipran—Dyspepsia—Vandetanib—thyroid cancer	0.00434	0.00434	CcSEcCtD
Milnacipran—Decreased appetite—Vandetanib—thyroid cancer	0.00428	0.00428	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00425	0.00425	CcSEcCtD
Milnacipran—Fatigue—Vandetanib—thyroid cancer	0.00425	0.00425	CcSEcCtD
Milnacipran—Angiopathy—Sorafenib—thyroid cancer	0.00424	0.00424	CcSEcCtD
Milnacipran—Mediastinal disorder—Sorafenib—thyroid cancer	0.00422	0.00422	CcSEcCtD
Milnacipran—Constipation—Vandetanib—thyroid cancer	0.00421	0.00421	CcSEcCtD
Milnacipran—Mental disorder—Sorafenib—thyroid cancer	0.0041	0.0041	CcSEcCtD
Milnacipran—Malnutrition—Sorafenib—thyroid cancer	0.00407	0.00407	CcSEcCtD
Milnacipran—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00403	0.00403	CcSEcCtD
Milnacipran—Delirium—Epirubicin—thyroid cancer	0.004	0.004	CcSEcCtD
Milnacipran—Dysgeusia—Sorafenib—thyroid cancer	0.00399	0.00399	CcSEcCtD
Milnacipran—Body temperature increased—Vandetanib—thyroid cancer	0.00389	0.00389	CcSEcCtD
Milnacipran—Abdominal pain—Vandetanib—thyroid cancer	0.00389	0.00389	CcSEcCtD
Milnacipran—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.00381	0.00381	CcSEcCtD
Milnacipran—Delirium—Doxorubicin—thyroid cancer	0.0037	0.0037	CcSEcCtD
Milnacipran—Syncope—Sorafenib—thyroid cancer	0.00365	0.00365	CcSEcCtD
Milnacipran—Leukopenia—Sorafenib—thyroid cancer	0.00364	0.00364	CcSEcCtD
Milnacipran—Loss of consciousness—Sorafenib—thyroid cancer	0.00358	0.00358	CcSEcCtD
Milnacipran—Asthenia—Vandetanib—thyroid cancer	0.00353	0.00353	CcSEcCtD
Milnacipran—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.00353	0.00353	CcSEcCtD
Milnacipran—Hypertension—Sorafenib—thyroid cancer	0.00352	0.00352	CcSEcCtD
Milnacipran—Pruritus—Vandetanib—thyroid cancer	0.00349	0.00349	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00344	0.00344	CcSEcCtD
Milnacipran—Dry mouth—Sorafenib—thyroid cancer	0.00339	0.00339	CcSEcCtD
Milnacipran—Diarrhoea—Vandetanib—thyroid cancer	0.00337	0.00337	CcSEcCtD
Milnacipran—Cystitis noninfective—Epirubicin—thyroid cancer	0.00336	0.00336	CcSEcCtD
Milnacipran—Cystitis—Epirubicin—thyroid cancer	0.00332	0.00332	CcSEcCtD
Milnacipran—Infection—Sorafenib—thyroid cancer	0.0033	0.0033	CcSEcCtD
Milnacipran—Shock—Sorafenib—thyroid cancer	0.00327	0.00327	CcSEcCtD
Milnacipran—Nervous system disorder—Sorafenib—thyroid cancer	0.00326	0.00326	CcSEcCtD
Milnacipran—Dizziness—Vandetanib—thyroid cancer	0.00326	0.00326	CcSEcCtD
Milnacipran—Thrombocytopenia—Sorafenib—thyroid cancer	0.00325	0.00325	CcSEcCtD
Milnacipran—Skin disorder—Sorafenib—thyroid cancer	0.00323	0.00323	CcSEcCtD
Milnacipran—Dry eye—Epirubicin—thyroid cancer	0.00318	0.00318	CcSEcCtD
Milnacipran—Anorexia—Sorafenib—thyroid cancer	0.00317	0.00317	CcSEcCtD
Milnacipran—Vomiting—Vandetanib—thyroid cancer	0.00313	0.00313	CcSEcCtD
Milnacipran—Bladder pain—Epirubicin—thyroid cancer	0.00311	0.00311	CcSEcCtD
Milnacipran—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00311	0.00311	CcSEcCtD
Milnacipran—Rash—Vandetanib—thyroid cancer	0.00311	0.00311	CcSEcCtD
Milnacipran—Dermatitis—Vandetanib—thyroid cancer	0.0031	0.0031	CcSEcCtD
Milnacipran—Headache—Vandetanib—thyroid cancer	0.00309	0.00309	CcSEcCtD
Milnacipran—Cystitis—Doxorubicin—thyroid cancer	0.00308	0.00308	CcSEcCtD
Milnacipran—Dyspnoea—Sorafenib—thyroid cancer	0.00296	0.00296	CcSEcCtD
Milnacipran—Dry eye—Doxorubicin—thyroid cancer	0.00294	0.00294	CcSEcCtD
Milnacipran—Nausea—Vandetanib—thyroid cancer	0.00293	0.00293	CcSEcCtD
Milnacipran—Dyspepsia—Sorafenib—thyroid cancer	0.00293	0.00293	CcSEcCtD
Milnacipran—Decreased appetite—Sorafenib—thyroid cancer	0.00289	0.00289	CcSEcCtD
Milnacipran—Bladder pain—Doxorubicin—thyroid cancer	0.00288	0.00288	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00287	0.00287	CcSEcCtD
Milnacipran—Fatigue—Sorafenib—thyroid cancer	0.00286	0.00286	CcSEcCtD
Milnacipran—Constipation—Sorafenib—thyroid cancer	0.00284	0.00284	CcSEcCtD
Milnacipran—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00272	0.00272	CcSEcCtD
Milnacipran—Renal failure acute—Epirubicin—thyroid cancer	0.00271	0.00271	CcSEcCtD
Milnacipran—Hot flush—Epirubicin—thyroid cancer	0.00267	0.00267	CcSEcCtD
Milnacipran—Menopausal symptoms—Epirubicin—thyroid cancer	0.00265	0.00265	CcSEcCtD
Milnacipran—Urticaria—Sorafenib—thyroid cancer	0.00264	0.00264	CcSEcCtD
Milnacipran—Abdominal pain—Sorafenib—thyroid cancer	0.00263	0.00263	CcSEcCtD
Milnacipran—Body temperature increased—Sorafenib—thyroid cancer	0.00263	0.00263	CcSEcCtD
Milnacipran—Hyponatraemia—Epirubicin—thyroid cancer	0.00251	0.00251	CcSEcCtD
Milnacipran—Renal failure acute—Doxorubicin—thyroid cancer	0.0025	0.0025	CcSEcCtD
Milnacipran—Hot flush—Doxorubicin—thyroid cancer	0.00247	0.00247	CcSEcCtD
Milnacipran—Migraine—Epirubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Milnacipran—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00245	0.00245	CcSEcCtD
Milnacipran—Hypersensitivity—Sorafenib—thyroid cancer	0.00245	0.00245	CcSEcCtD
Milnacipran—Asthenia—Sorafenib—thyroid cancer	0.00238	0.00238	CcSEcCtD
Milnacipran—Pruritus—Sorafenib—thyroid cancer	0.00235	0.00235	CcSEcCtD
Milnacipran—Hyponatraemia—Doxorubicin—thyroid cancer	0.00232	0.00232	CcSEcCtD
Milnacipran—Liver function test abnormal—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Milnacipran—Dry skin—Epirubicin—thyroid cancer	0.00229	0.00229	CcSEcCtD
Milnacipran—Migraine—Doxorubicin—thyroid cancer	0.00228	0.00228	CcSEcCtD
Milnacipran—Diarrhoea—Sorafenib—thyroid cancer	0.00227	0.00227	CcSEcCtD
Milnacipran—Breast disorder—Epirubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Milnacipran—Dizziness—Sorafenib—thyroid cancer	0.0022	0.0022	CcSEcCtD
Milnacipran—Abdominal distension—Epirubicin—thyroid cancer	0.00217	0.00217	CcSEcCtD
Milnacipran—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Milnacipran—Dry skin—Doxorubicin—thyroid cancer	0.00212	0.00212	CcSEcCtD
Milnacipran—Vomiting—Sorafenib—thyroid cancer	0.00211	0.00211	CcSEcCtD
Milnacipran—Angina pectoris—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Milnacipran—Rash—Sorafenib—thyroid cancer	0.0021	0.0021	CcSEcCtD
Milnacipran—Dermatitis—Sorafenib—thyroid cancer	0.00209	0.00209	CcSEcCtD
Milnacipran—Breast disorder—Doxorubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Milnacipran—Headache—Sorafenib—thyroid cancer	0.00208	0.00208	CcSEcCtD
Milnacipran—Neutropenia—Epirubicin—thyroid cancer	0.00202	0.00202	CcSEcCtD
Milnacipran—Dysuria—Epirubicin—thyroid cancer	0.00202	0.00202	CcSEcCtD
Milnacipran—Abdominal distension—Doxorubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Milnacipran—Pollakiuria—Epirubicin—thyroid cancer	0.00199	0.00199	CcSEcCtD
Milnacipran—Nausea—Sorafenib—thyroid cancer	0.00197	0.00197	CcSEcCtD
Milnacipran—Weight decreased—Epirubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Milnacipran—Angina pectoris—Doxorubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00191	0.00191	CcSEcCtD
Milnacipran—Urinary tract infection—Epirubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Milnacipran—Dysuria—Doxorubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Milnacipran—Neutropenia—Doxorubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Milnacipran—Pollakiuria—Doxorubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Milnacipran—Haematuria—Epirubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Milnacipran—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00182	0.00182	CcSEcCtD
Milnacipran—Weight decreased—Doxorubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Milnacipran—Urinary tract infection—Doxorubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Milnacipran—Hepatitis—Epirubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Milnacipran—Hypoaesthesia—Epirubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Milnacipran—Urinary tract disorder—Epirubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Milnacipran—Oedema peripheral—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Haematuria—Doxorubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Connective tissue disorder—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Milnacipran—Urethral disorder—Epirubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Milnacipran—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Milnacipran—Erythema multiforme—Epirubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Milnacipran—Eye disorder—Epirubicin—thyroid cancer	0.00162	0.00162	CcSEcCtD
Milnacipran—Flushing—Epirubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Milnacipran—Cardiac disorder—Epirubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Milnacipran—Hepatitis—Doxorubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Milnacipran—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Milnacipran—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Milnacipran—Oedema peripheral—Doxorubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Milnacipran—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Milnacipran—Angiopathy—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Milnacipran—Urethral disorder—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Milnacipran—Mediastinal disorder—Epirubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Milnacipran—Chills—Epirubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Milnacipran—Mental disorder—Epirubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Milnacipran—Erythema multiforme—Doxorubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Milnacipran—Malnutrition—Epirubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Milnacipran—Eye disorder—Doxorubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Milnacipran—Flushing—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Milnacipran—Cardiac disorder—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Milnacipran—Flatulence—Epirubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Milnacipran—Tension—Epirubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Milnacipran—Dysgeusia—Epirubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Milnacipran—Angiopathy—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Milnacipran—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Milnacipran—Chills—Doxorubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Milnacipran—Vision blurred—Epirubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Milnacipran—Mental disorder—Doxorubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Milnacipran—Malnutrition—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Milnacipran—Agitation—Epirubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Milnacipran—Flatulence—Doxorubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Milnacipran—Tension—Doxorubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Milnacipran—Dysgeusia—Doxorubicin—thyroid cancer	0.00136	0.00136	CcSEcCtD
Milnacipran—Syncope—Epirubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Milnacipran—Leukopenia—Epirubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Milnacipran—Palpitations—Epirubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Milnacipran—Loss of consciousness—Epirubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Milnacipran—Vision blurred—Doxorubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Milnacipran—Convulsion—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Milnacipran—Hypertension—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Milnacipran—Chest pain—Epirubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Milnacipran—Agitation—Doxorubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Milnacipran—Anxiety—Epirubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Milnacipran—Dry mouth—Epirubicin—thyroid cancer	0.00125	0.00125	CcSEcCtD
Milnacipran—Syncope—Doxorubicin—thyroid cancer	0.00125	0.00125	CcSEcCtD
Milnacipran—Leukopenia—Doxorubicin—thyroid cancer	0.00125	0.00125	CcSEcCtD
Milnacipran—Palpitations—Doxorubicin—thyroid cancer	0.00123	0.00123	CcSEcCtD
Milnacipran—Loss of consciousness—Doxorubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Milnacipran—Infection—Epirubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Milnacipran—Shock—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Milnacipran—Convulsion—Doxorubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Milnacipran—Nervous system disorder—Epirubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Milnacipran—Thrombocytopenia—Epirubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Milnacipran—Hypertension—Doxorubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Milnacipran—Tachycardia—Epirubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Milnacipran—Skin disorder—Epirubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Milnacipran—Hyperhidrosis—Epirubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Milnacipran—Chest pain—Doxorubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Milnacipran—Anxiety—Doxorubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Milnacipran—Anorexia—Epirubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Milnacipran—Dry mouth—Doxorubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Milnacipran—Hypotension—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Milnacipran—Infection—Doxorubicin—thyroid cancer	0.00113	0.00113	CcSEcCtD
Milnacipran—Shock—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Milnacipran—Nervous system disorder—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Milnacipran—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Milnacipran—Insomnia—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Milnacipran—Tachycardia—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Milnacipran—Skin disorder—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Milnacipran—Paraesthesia—Epirubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Milnacipran—Hyperhidrosis—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Milnacipran—Dyspnoea—Epirubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Milnacipran—Somnolence—Epirubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Milnacipran—Anorexia—Doxorubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Milnacipran—Dyspepsia—Epirubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Milnacipran—Decreased appetite—Epirubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Milnacipran—Hypotension—Doxorubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Milnacipran—Fatigue—Epirubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Milnacipran—Constipation—Epirubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Milnacipran—Insomnia—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Milnacipran—Paraesthesia—Doxorubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Milnacipran—Dyspnoea—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Milnacipran—Somnolence—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Milnacipran—Gastrointestinal pain—Epirubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Milnacipran—Dyspepsia—Doxorubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Milnacipran—Decreased appetite—Doxorubicin—thyroid cancer	0.000988	0.000988	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000981	0.000981	CcSEcCtD
Milnacipran—Fatigue—Doxorubicin—thyroid cancer	0.00098	0.00098	CcSEcCtD
Milnacipran—Urticaria—Epirubicin—thyroid cancer	0.000976	0.000976	CcSEcCtD
Milnacipran—Constipation—Doxorubicin—thyroid cancer	0.000972	0.000972	CcSEcCtD
Milnacipran—Abdominal pain—Epirubicin—thyroid cancer	0.000971	0.000971	CcSEcCtD
Milnacipran—Body temperature increased—Epirubicin—thyroid cancer	0.000971	0.000971	CcSEcCtD
Milnacipran—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000929	0.000929	CcSEcCtD
Milnacipran—Hypersensitivity—Epirubicin—thyroid cancer	0.000905	0.000905	CcSEcCtD
Milnacipran—Urticaria—Doxorubicin—thyroid cancer	0.000903	0.000903	CcSEcCtD
Milnacipran—Body temperature increased—Doxorubicin—thyroid cancer	0.000898	0.000898	CcSEcCtD
Milnacipran—Abdominal pain—Doxorubicin—thyroid cancer	0.000898	0.000898	CcSEcCtD
Milnacipran—Asthenia—Epirubicin—thyroid cancer	0.000881	0.000881	CcSEcCtD
Milnacipran—Pruritus—Epirubicin—thyroid cancer	0.000869	0.000869	CcSEcCtD
Milnacipran—Diarrhoea—Epirubicin—thyroid cancer	0.00084	0.00084	CcSEcCtD
Milnacipran—Hypersensitivity—Doxorubicin—thyroid cancer	0.000837	0.000837	CcSEcCtD
Milnacipran—Asthenia—Doxorubicin—thyroid cancer	0.000815	0.000815	CcSEcCtD
Milnacipran—Dizziness—Epirubicin—thyroid cancer	0.000812	0.000812	CcSEcCtD
Milnacipran—Pruritus—Doxorubicin—thyroid cancer	0.000804	0.000804	CcSEcCtD
Milnacipran—Vomiting—Epirubicin—thyroid cancer	0.000781	0.000781	CcSEcCtD
Milnacipran—Diarrhoea—Doxorubicin—thyroid cancer	0.000777	0.000777	CcSEcCtD
Milnacipran—Rash—Epirubicin—thyroid cancer	0.000774	0.000774	CcSEcCtD
Milnacipran—Dermatitis—Epirubicin—thyroid cancer	0.000774	0.000774	CcSEcCtD
Milnacipran—Headache—Epirubicin—thyroid cancer	0.000769	0.000769	CcSEcCtD
Milnacipran—Dizziness—Doxorubicin—thyroid cancer	0.000751	0.000751	CcSEcCtD
Milnacipran—Nausea—Epirubicin—thyroid cancer	0.000729	0.000729	CcSEcCtD
Milnacipran—Vomiting—Doxorubicin—thyroid cancer	0.000722	0.000722	CcSEcCtD
Milnacipran—Rash—Doxorubicin—thyroid cancer	0.000716	0.000716	CcSEcCtD
Milnacipran—Dermatitis—Doxorubicin—thyroid cancer	0.000716	0.000716	CcSEcCtD
Milnacipran—Headache—Doxorubicin—thyroid cancer	0.000712	0.000712	CcSEcCtD
Milnacipran—Nausea—Doxorubicin—thyroid cancer	0.000675	0.000675	CcSEcCtD
